Editorial: Calcitonin Gene-Related Peptide: Novel Biology and Treatments
- PMID: 35928563
- PMCID: PMC9344364
- DOI: 10.3389/fphys.2022.964568
Editorial: Calcitonin Gene-Related Peptide: Novel Biology and Treatments
Keywords: CGRP–Calcitonin Gene-Related Peptide; adverse (side) effects; antibodies and antagonists; cardiovascular disease; migraine; receptor; receptor (biochemistry).
Conflict of interest statement
SB is a speaker and consultant for Eli Lilly. AR is a consultant for Lundbeck, Eli Lilly, AbbVie, and Schedule One Therapeutics. The contents do not represent the views of the Veterans Administration or the United States Government and receives research support from Lundbeck, the National Institutes of Health, and the Veterans Administration. DH is a speaker or consultant for Amgen, Eli Lilly, Teva and has received research support from AbbVie.
Comment on
- Editorial on the Research TopicCalcitonin Gene-Related Peptide: Novel Biology and Treatments
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
